On the heels of basic research on the venom of Gila monsters in the preceding decades,1 exenatide secured the first US FDA approval in the class on April 28, 2005.2 While the prominent GLP-1 brand names are household names today, the class was off to a relatively slow start at first five years passed before it reached blockbuster status (US$1 billion (770 million) in sales), and another five went by before the first formal approval of a GLP-1 drug indicated for obesity became a reality.3 Last year saw sales for the class cross $50 billion and, with another 40% in revenue growth in store for 2025, the GLP-1 segment of the pharmaceutical industry is firmly in the rapid growth phase of the market, per Investment Bank Consensus
The competitive environment within the GLP-1 Drug Market is intensifying, as established players and new entrants alike strive to capture market share
It is critical for antioxidant protection and overall cellular health
It has taken the place of OZEMPIC globally a famous semaglutide by NovoNordisk
Follow us: 2026 Equalan Pharma
9) Sohonos (palovarotene) (PG183, Ver
